US High Growth Tech Stocks with Promising Potential
Arista Networks Inc ANET | 0.00 |
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 26%, with earnings expected to grow by 16% per annum in the coming years. In this environment of steady growth and promising earnings projections, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging technological trends.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.01% | 21.70% | ★★★★★★ |
| 21.89% | 25.35% | ★★★★★★ | |
| Sandisk | 39.21% | 38.34% | ★★★★★★ |
| Krystal Biotech | 29.09% | 36.48% | ★★★★★★ |
| Palantir Technologies | 30.22% | 31.80% | ★★★★★★ |
| Fabrinet | 21.38% | 23.34% | ★★★★★★ |
| Zscaler | 14.46% | 55.60% | ★★★★★☆ |
| Marker Therapeutics | 64.28% | 69.04% | ★★★★★★ |
| Tenaya Therapeutics | 59.68% | 60.87% | ★★★★★☆ |
| KVH Industries | 28.67% | 146.09% | ★★★★★☆ |
Let's uncover some gems from our specialized screener.
ADMA Biologics (ADMA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases in the United States and internationally, with a market cap of $1.80 billion.
Operations: The company generates revenue primarily through its ADMA Biomanufacturing segment, which accounts for $493.03 million, while its Plasma Collection Centers contribute $16.70 million.
ADMA Biologics, despite a challenging year with a 20% earnings decline, is poised for recovery with expected annual earnings growth of 21.6%, outpacing the US market's forecast of 16.2%. This biotech firm recently secured FDA approval for ASCENIV in younger patients, broadening its market potential significantly. With revenue growth also projected to exceed the national average at 15.6% annually, ADMA is strategically expanding its influence in immunodeficiency treatments while enhancing shareholder value through robust financial management and innovative R&D initiatives.
Arista Networks (ANET)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Arista Networks, Inc. develops, markets, and sells data-driven networking solutions for AI, data centers, campuses, and routing environments globally with a market cap of $219.57 billion.
Operations: The company generates revenue primarily from its Computer Networks segment, amounting to $9.71 billion. Its operations span across various regions, including the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
Arista Networks has demonstrated robust financial performance, with a significant year-over-year revenue increase from $2 billion to $2.71 billion in Q1 2026, and net income rising from $813.8 million to $1.02 billion in the same period. This growth trajectory is complemented by an innovative R&D focus, as evidenced by the launch of XPO optics modules designed for AI networking, which deliver unprecedented throughput and cooling efficiency. These strategic advancements not only underscore Arista's commitment to leading-edge technology but also position it well for sustained growth in a competitive sector where demand for enhanced network capabilities is escalating.
Sprinklr (CXM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Sprinklr, Inc. offers enterprise cloud software solutions on a global scale and has a market capitalization of $1.36 billion.
Operations: Sprinklr generates revenue primarily from its Software & Programming segment, which reported $871.18 million. The company's market capitalization is approximately $1.36 billion.
Sprinklr's recent performance showcases a significant turnaround with Q1 2026 revenue rising to $219.48 million from $205.5 million year-over-year, and a shift from a net loss of $1.57 million to a net income of $4.18 million. This improvement is underscored by strategic R&D investments, which are pivotal in driving innovation and maintaining competitive edge in the rapidly evolving tech landscape. The company's commitment to expanding its technological capabilities is evident from its recent share repurchase program, where it bought back shares worth $125 million, signaling confidence in its future growth trajectory. Moreover, the launch of the Sprinklr Social Index highlights their focus on bridging the gap between brand presence and consumer engagement through advanced analytics, setting a new standard in customer interaction for the industry.
Summing It All Up
- Take a closer look at our US High Growth Tech and AI Stocks list of 70 companies by clicking here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
